Showing results (181-190 of 419) with videos related to
Sort By:
Pageof 42
NPJ Precision Oncology|January 29, 2026
A unified framework for pre-screening and screening tools in oncology clinical trialsDenis Horgan, Joe Paulson, Arturo Loaiza-Bonilla, et al.Journal of Computer Assisted Tomography|December 1, 2017
Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver TumorsPayel Ghosh, Adam G Chandler, Brian P Hobbs, et al.Diagnosis (Berlin, Germany)|December 17, 2024
Challenges and barriers for the adoption of personalized medicine in Europe: the case of Oncotype DX Breast Recurrence Score® testDenis Horgan, Paul Hofman, Patrizio Giacomini, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2017
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue SarcomaVivek Subbiah, Christian Meyer, Ralph Zinner, et al.Oral Oncology|January 14, 2026
Incorporation of grade into stage in oral cavity squamous cell carcinoma: A novel staging schemaAllen S Ho, Michael Luu, Daniel Manzoor, et al.Journal of Hematology & Oncology|January 16, 2014
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion proteinVivek Subbiah, Shannon N Westin, Kai Wang, et al.The Oncologist|September 13, 2021
Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 TrialLori J Wirth, Bruce Robinson, Valentina Boni, et al.Cell Reports. Medicine|December 20, 2023
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancersMirella Nardo, Mohamed A Gouda, Blessie E Nelson, et al.Lung Cancer (Amsterdam, Netherlands)|May 19, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastasesVivek Subbiah, Jenny Berry, Michael Roxas, et al.JAMA Network Open|November 3, 2022
Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology AssessmentSreeram V Ramagopalan, Sanjay Popat, Alind Gupta, et al.Pageof 42